Home » Stocks » TALS

Talaris Therapeutics, Inc. (TALS)

Stock Price: $13.83 USD -0.54 (-3.76%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 570.31M
Revenue (ttm) n/a
Net Income (ttm) -22.71M
Shares Out 41.24M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $13.83
Previous Close $14.37
Change ($) -0.54
Change (%) -3.76%
Day's Open 14.37
Day's Range 13.68 - 14.48
Day's Volume 271,925
52-Week Range 12.70 - 17.50

News

Hide News

BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...

3 days ago - GlobeNewsWire

BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of c...

1 week ago - GlobeNewsWire

Talaris Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

4 weeks ago - SEC

About TALS

Talaris Therapeutics is a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that we believe has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. In the organ transplant setting, which is our initial focus, we believe our proprietary therapeutic approach, which we call Facilitated Allo-HSCT Therapy, could prevent organ re... [Read more...]

Industry
Biological Products
IPO Date
May 7, 2021
CEO
Scott Requadt
Employees
82
Stock Exchange
NASDAQ
Ticker Symbol
TALS
Full Company Profile

Financial Performance

Financial Statements